Therapeutic History of Chelation Therapy
Chelation (pronounced
KEY-LAY-SHUN) is a treatment by which a small amino acid called ethylene
diamine tetraacetic acid (commonly abbreviated EDTA) is slowly administered
to a patient intravenously over several hours, prescribed by and under the
supervision of a licensed physician. The fluid containing EDTA is infused
through a small needle placed in the vein of a patient’s arm. The EDTA
infusion, bonds with unwanted metals in the body, and quickly carries them
away in the urine. .
EDTA was first introduced into
medicine in the United States in 1948 as a treatment for industrial workers
suffering from lead poisoning in a battery factory. Shortly thereafter, the
U.S. Navy advocated chelation therapy for sailors who had absorbed lead
while painting government ships and dock facilities. In the years since,
chelation therapy has remained the undisputed treatment-of-choice for lead
poisoning, even in children with toxic accumulations of lead in their bodies
as a result of eating leaded paint from toys, cribs or walls.
50+ Year of Proof:
Chelation Could Save Hundreds of
Thousands of Lives....Every Year
Clinical experience with EDTA chelation therapy has convinced substantial
numbers of licensed physicians in North America that it is a safe and
effective treatment for atherosclerotic vascular disease, as it consistently
improves blood flow and relieves symptoms associated with the disease in
greater than 80% of the patients treated. As members of the medical
profession are generally aware, the pathogenesis of atherosclerotic disease
is extraordinarily complex.
Nineteen Out of 20 Heart
Patients Enjoyed Measurable
Improvement in Energy and Activity Level
The scientific principles underlying the
efficacy of EDTA chelation therapy in impeding each step of the disease
process are beyond the scope of this article, but they are elaborated upon
in the many published clinical studies and research papers available. In its
simplest terms, the rationale for its efficacy is that EDTA, in binding
ionic metal catalysts and removing them from the body, reduces subsequent
abnormal production of oxygen free radical reactive molecules and molecular
fragments which react destructively with other molecules. See, E. M. Cranton,
J. P. Frackelton, Free Radical Pathology in Age-Associated Diseases:
Treatment with EDTA Chelation, Nutrition, and Antioxidants, Journal of
Advancement in Medicine, Vol. 2, Nos. 1, 2, Spring/Summer, 1989.1
Introduction
The National Center for Complementary and
Alternative Medicine (NCCAM) and the National Heart, Lung, and Blood
Institute (NHLBI), both components of the National Institutes of Health (NIH),
have launched the Trial To Assess Chelation Therapy (TACT). TACT is the
first large-scale, multicenter study to determine the safety and efficacy of
EDTA chelation therapy for individuals with coronary artery disease. The
questions and answers below provide additional information on coronary
artery disease, EDTA chelation therapy, and the study.
What is EDTA chelation therapy?
Chelation is a chemical process in which a substance
is used to bind molecules, such as metals or minerals, and hold them tightly
so that they can be removed from a system, such as the body. In medicine, chelation has been scientifically proven to rid the body of excess or toxic
metals. For example, a person who has lead poisoning may be given chelation
therapy in order to bind and remove excess lead from the body before it can
cause damage.
In the case of EDTA chelation therapy, the substance
that binds and removes metals and minerals is EDTA (ethylene diamine
tetra-acetic acid), a synthetic, or man-made, amino acid that is delivered
intravenously (through the veins). EDTA was first used in the 1940s for the
treatment of heavy metal poisoning. EDTA chelation removes heavy metals and
minerals from the blood, such as lead, iron, copper, and calcium, and is
approved by the U.S. Food and Drug Administration (FDA) for use in treating
lead poisoning and toxicity from other heavy metals. Although it is not
approved by the FDA to treat CAD, some physicians and alternative medicine
practitioners have recommended EDTA chelation as a way to treat this
disorder.
EDTA is NOT a drug. It is not quite a vitamin, since
it is an \"artificial\" amino acid, but the patent on it ran out long ago
and there is no profit left in making it -- so you will not see much
promotion of it. IV chelation has, unfortunately, gotten into a price war
among the doctors -- so they cannot charge what this treatment is really
worth. IV doctors normally charge about $100 per treatment, and that is far
less than it is worth.
Oral chelation is, of course, a fantastic health bargain since it delivers
so much benefit at such a low cost.
How might EDTA chelation therapy work to
clear blocked arteries?
Several theories have been suggested by those who
recommend this form of treatment. One theory suggests that EDTA chelation
might work by directly removing calcium found in fatty plaques that block
the arteries, causing the plaques to break up. Another is that the process
of chelation may stimulate the release of a hormone that in turn causes
calcium to be removed from the plaques or causes a lowering of cholesterol
levels. A third theory is that
EDTA chelation therapy may work by reducing
the damaging effects of oxygen ions (oxidative stress) on the walls of the
blood vessels. Reducing oxidative stress could reduce inflammation in the
arteries and improve blood vessel function. None of these theories has been
well tested in scientific studies.
How frequently is EDTA chelation therapy
used?
It is estimated by the American College for
Advancement in Medicine (ACAM), a professional association that supports the
use of chelation therapy, that more than 800,000 visits for chelation
therapy were made in the United States in 1997 alone. *
*Health statements have
not been evaluated by the FDA. We always recommend you check with your
health care practitioner or physician prior to beginning any new
supplement or diet program, especially if you are on any medication,
nursing, pregnant or have any other existing medical condition.
REFERENCES
Bjorksten J: Longevity, a quest. Madison, WI,
Bjorksten Research Foundation, 1981.
Chemical Society: Stability constants. Oxford, ENG,
Alden & Mobray, Ltd, Alden Press (Special Publication 25) 1971.
Halstead B Rozema T: The Scientific basis of EDTA
chelation therapy, Landrum, SC, TRC Publishing, 2d Ed, 1997.
Halstead B: Chelation therapy. Palm Desert, CA,
(published in cooperation with) Ameri Acad Med Preventics, 1975.
Julian J: Chelation extends life. Hollywood,
Wellness Press, 1981.
Olmstead SF Steward DK: Characterization of the
patient population with coronary artery disease undergoing chelation therapy
with disodium magnesium-ethylenediamine tetraacetate.
Reprints of Medical Literature on Chelation Therapy,
1978.
Sacramento Medical Preventics Clinic, Inc: Lead
toxicity. Sacramento, December 1974.
Soffer A Chenoweth M Eichhorn GL Rosoff B Rubin M
Spencer H: Chelation therapy. Springfield, IL, Charles C. Thomas Publishing,
1964.
U.S. Department of Health, Education, and Welfare
(Public Health Service, National Institutes of Health): Symposium on
development of iron chelators for clinical use. Bethesda, MD, DHEW
Publication No. (NIH) 77-994, WF Anderson and MC Hiller, editors, 1975.
US Dept of Health, Education and Welfare: Increased
lead absorption and lead poisoning in young children—A statement by the
Center for Disease Control, USD of HEW pub #00-2629, March, 1975.
Walker M Trowbridge J: Chelation therapy-better
health. Greenwich, Cn, Devin-Adair Publishing, 1965.
Walker M: The chelation way—The complete book of
chelation therapy. Garden City Park, NY, Avery Publishing Group, Inc, 1990.
Walker M: The miracle healing power of chelation
therapy—the intravenous and oral treatment for reversal and prevention of
hardening of the arteries and other common degenerative diseases. Canfield,
OH, Fischer Publishing, 1984.
Walter M Gordon GF: The chelation answer-How to
prevent hardening of the arteries and rejuvenate your cardiovascular system.
New York, M.Evans and Company, Inc., 1982.